12:02 PM EDT, 08/30/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Friday that additional data from a phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy or ATTR-CM showed that switching from standard of care treatment and placebo to acoramidis increased serum transthyretin at the first month.

The increase in serum transthyretin or TTR was correlated with reduced risk of all-cause mortality, cardiovascular mortality, and cardiovascular-related hospitalization in participants with ATTR-CM, the company said. BridgeBio Pharma ( BBIO ) previously reported study results that showed acoramidis treatment led to increased serum TTR levels by day 28 and was sustained over 30 months.

BridgeBio Pharma ( BBIO ) said it used the study's positive results as the basis for its US new drug application and European marketing authorization application for acoramidis. The company said its US NDA has a target action date of Nov. 29, while the decision on its application in Europe is expected in 2025.

Shares of BridgeBio Pharma ( BBIO ) were up more than 11% in recent trading.

Price: 27.49, Change: +2.87, Percent Change: +11.66